olfactory receptor family 13 subfamily C member 7 (gene/pseudogene)Genealiases: OR13C7P · OR37C · OST706
Q-omics provides the consensus-scored OR13C7 profile across patient tissues and cancer cell-line models. OR13C7 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, OR13C7 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, OR13C7 RNA expression shows 6,058 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and LUSC as cancer lineages where OR13C7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR13C7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR13C7 survival associations across molecular data types. OR13C7 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR13C7 RNA expression–survival associations across cancer types. High OR13C7 expression shows unfavorable associations in STAD, ESCA, UCEC, DLBC, KIRP and MESO. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for OR13C7 RNA expression.
This table summarizes OR13C7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR13C7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR13C7 shows lower tumor expression in LUSC, LUAD, BRCA, KICH and COAD. The LUSC box plot shows higher OR13C7 RNA expression in normal versus tumor tissue (log2 FC = −0.028, t-test p < 0.001).
This table shows molecular features associated with OR13C7 in patient tissues and cancer cell lines. In patient samples, OR13C7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR13C7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
